Protalix Reports Phase I Clinical Study Results for PRX-106 Showed Favorable Safety, Tolerability Profile Activity

By: via Benzinga
Protalix BioTherapeutics, Inc. (NYSE: PLX) announced today positive clinical study results from the Company's Phase I trial of PRX-106, ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.